ViiV Healthcare has once again demonstrated its commitment to patient-centric practices, reclaiming the number one position in the latest U.S.-specific reputation survey conducted by PatientView. This accolade follows the company\u2019s successful ranking in the global version of the survey, marking a continued ascent in patient group esteem after slipping from its previous standings in recent years. The survey’s results provide valuable insights into the pharmaceutical industry’s perception among U.S. patient advocates, representing the voices of over 13 million patients across various therapeutic areas including cancer, rare diseases, and neurological conditions.<\/p>\n
The latest report released by PatientView summarizes findings from a survey conducted over several months\u2014from December 2024 to March 2025. In total, 372 patient groups were surveyed, rating the reputation of 40 global pharmaceutical companies in regard to their performance and integrity in the healthcare realm. In a compelling repeat of past accolades, ViiV Healthcare emerged as the frontrunner, overtaking Servier and Amgen, last year’s leaders in patient group satisfaction.<\/p>\n
In this year’s evaluation, respondents not only ranked the general corporate reputations of these major pharmaceutical companies but also provided ratings based on their direct experiences with these firms. Impressively, ViiV Healthcare was highly rated even by its peers. Specifically, when the criteria were narrowed solely to firms with which the patient groups had direct interactions, ViiV once again led the way, followed closely by Servier and Amgen.<\/p>\n
The survey also gathered input on the overall perceptions of the pharmaceutical industry in the U.S. A notable 60% of patient groups rated the industry\u2019s reputation as either \u201cgood\u201d or \u201cexcellent,\u201d indicating a positive shift from the previous year’s figures\u2014up from 57%\u2014and surpassing this year\u2019s global survey findings of 56% in support for the industry as a whole. Despite this positive trend, the pharmacological industry still falls behind its biotech counterparts, where a striking 74% of patient advocates reflected a positive view.<\/p>\n
To delve deeper into the aspects of performance, the survey showed that ratings for various qualities perceived by patient groups saw a considerable decline since 2020. The most notable decreases were seen in integrity, patient safety, and patient-centricity, which fell by 15, 14, and 10 percentage points respectively over four years. Despite the downward trend in most performance categories, a slight improvement was recorded in pricing transparency, which rose by a single percentage point. Transparency in funding has notably remained stable at a positive rating of 32% since 2020.<\/p>\n
The survey did highlight some strengths in the pharmaceutical industry\u2019s performance, particularly in areas that directly benefit patients. A commendable 77% of patient groups rated the industry’s product offerings as \u201cgood\u201d or \u201cexcellent\u201d\u2014a testament to the pharmaceutical sector’s ongoing commitment to innovation. Other aspects that received positive feedback included:<\/p>\n
However, integrity, albeit high in importance, saw its ratings dip slightly below the half mark, with only 49% of patient groups viewing this quality favorably.<\/p>\n
In summary, ViiV Healthcare\u2019s return to the forefront of pharma reputation rankings shines a light on the importance of accountability and transparency within the industry. While the overall perception of the pharmaceutical industry has improved, critical areas still require attention and improvement, particularly concerning integrity and other patient-centric practices. Future opportunities exist for all pharmaceutical companies to enhance their standing among patient groups by addressing these challenges head-on. ViiV’s ongoing dedication to prioritizing patient needs serves as an exemplary model for others in the industry.<\/p>\n","protected":false},"excerpt":{"rendered":"
ViiV Healthcare Reclaims Top Spot in Pharma Reputation Ranking Among U.S. Patient Groups ViiV Healthcare has once again demonstrated its commitment to patient-centric practices, reclaiming the number one position in the latest U.S.-specific reputation survey conducted by PatientView. This accolade follows the company\u2019s successful ranking in the global version of the survey, marking a continued…<\/p>\n","protected":false},"author":32,"featured_media":10735,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_eb_attr":"","footnotes":""},"categories":[685],"tags":[],"class_list":["post-10736","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharma-stocks"],"_links":{"self":[{"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/posts\/10736","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/comments?post=10736"}],"version-history":[{"count":0,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/posts\/10736\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/media\/10735"}],"wp:attachment":[{"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/media?parent=10736"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/categories?post=10736"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/tags?post=10736"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}